VANCOUVER, British Columbia, Feb. 09 2022 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLBF), (Frankfurt: LD6WKN: A3CSSU) (the “Society” Where “core one”) is pleased to announce that following its landmark announcement, its wholly-owned subsidiary, Vocan Biotechnologies Inc. (Vocabulary), has successfully engineered a novel recombinant production system for biologically synthesized (biosynthesized) psilocybin and has filed for patent protection for its breakthrough intellectual property (see Core One press release dated January 21, 2022), its team of scientists continues to make progress and are in the process of optimizing large-scale production capacity.
The increased production of the company’s breakthrough biosynthetic psilocybin and the approval of the company’s patent application will position Core One and Vocan to become a significant player in the supply of cost-effective psilocybin and have the potential to change significantly the face of psilocybin-based psychedelics. mental health care and patient access to alternative treatment worldwide.
Psilocybin is a psychedelic compound with great promise in the treatment of drug addiction and many mental health disorders. and the success of this game-changing patent propels Core One to the forefront of the growing psychedelic industry, eliminating barriers to psychedelic treatment and research such as exorbitant costs and lack of availability and supply. .
Currently, most companies use chemically synthesized psilocybin as the only available GMP product available in large quantities. The chemical process incurs significant costs and is less efficient compared to a biologically derived psilocybin.
Led by Dr. Jan Burian, Vocan’s Chief Scientist, and Dr. Robert EW Hancock, Vocan’s CEO, the team’s revolutionary psilocybin production method utilizes the well-established industrial process of fermentation and can therefore be scaled to scale while consistently producing a high quality cGMP product. The process turns bacteria into a biological factory to produce synthesized psilocybin, dramatically reducing cost and time.
With Vocan’s optimized recombinant production system, the subsidiary has successfully tested its proof of concept for the manufacture of biosynthetic psilocybin suitable for future large-scale use and is awaiting patent approval. The application includes claims that Vocan’s technology will enable the production of cGMP API-grade psilocybin, which can be used by pharmaceutical companies, API manufacturers and organizations conducting clinical trials and, where permitted by law , consumers and patients. Vocan’s crucial breakthrough anticipates a ripple effect that could reshape the industry landscape going forward.
“This breakthrough in psilocybin production may change the entire industry. By making psychedelic treatments cost-effective, it could make treatment more widely available to patients around the world. In addition, our patent on this process gives us the advantage of being the first in this important and emerging space,said Joel Shacker, CEO of the company.
About Core One Labs Inc.
Core One is a biotechnology research and life science technology company focused on bringing psychedelic drugs to market through novel delivery systems and psychedelic-assisted psychotherapy. Core One has developed a patent-pending thin-film oral strip (the “Technology”) that dissolves instantly when placed in the mouth and delivers organic molecules in precise amounts into the bloodstream, maintaining excellent bioavailability . The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also has interests in medical clinics that maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for the disorders of mental health.
Core One Labs Inc.
Chief executive officer
FOR MORE INFORMATION PLEASE CONTACT:
The Canadian Securities Exchange has not reviewed and accepts no responsibility for the adequacy or accuracy of the content of this press release.
The information in this press release contains forward-looking statements based on assumptions as of the date of this press release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of important factors, many of which are beyond the Company’s control. These factors include, among others: the risks and uncertainties associated with the Company’s limited operating history and the need to comply with stringent regulatory regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied by the forward-looking information. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking information.
In addition, psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada) and it is a criminal offense to possess substances under the Controlled Drugs and Substances Act (Canada) without a prescription or authorization. Health Canada has not approved psilocybin as a drug for any indication. Core One has no direct or indirect involvement in the illegal sale, production or distribution of psychedelic substances in the jurisdictions in which it operates. Although Core One believes that psychedelics can be used to treat certain medical conditions, it does not advocate the legalization of psychedelics for recreational use. Core One does not deal with psychedelics except in laboratory and clinical trials conducted under approved regulatory frameworks.